In this webinar, Jeff discusses Chameleon’s EVADER™ gene therapy platform, which is designed to evade the immune system, overcome the neutralizing immune response, expand the treatable patient population, and enable multiple dosing. The platform encapsulates AAVs in a lipid bilayer with specific immune cell inhibitors and has demonstrated increased infectivity, delivery, and transgene expression in preclinical models. The EVADER™ platform is currently being used to develop gene therapies for multiple diseases in collaboration with biotech and pharmaceutical companies.